Does Requip Cause Extreme Daytime Sleepiness?
Yes, Requip (ropinirole), used for Parkinson's disease and restless legs syndrome, causes sudden, extreme daytime sleepiness or "sleep attacks" in some patients. These episodes can occur without warning, even during daily activities like driving, and patients may not feel drowsy beforehand.[1][2]
How Common Are Sleep Attacks with Requip?
Reports show sleepiness affects 2-12% of users, depending on dose and condition. In clinical trials, about 2% experienced sudden sleep onset, higher than placebo. Post-marketing data from FDA reports link it to hundreds of cases, including accidents.[1][3]
Why Does This Happen?
Requip stimulates dopamine receptors in the brain, mimicking dopamine to treat movement disorders. This overstimulates sleep-regulating pathways, leading to irresistible sleepiness. Risk rises with higher doses (over 6 mg/day for RLS) and in Parkinson's patients.[2][4]
What Do Patients Report?
Users describe falling asleep mid-conversation, at work, or while driving. FDA warnings highlight 154 cases by 2005, with 21 traffic accidents and one fatality. Many report no prior fatigue warning.[3][5]
Compared to Similar Drugs?
Requip shares this risk with other dopamine agonists like Mirapex (pramipexole) and Neupro (rotigotine), all carrying black-box warnings for somnolence. Sinemet (carbidopa-levodopa) has lower rates but different side effects.[1][2]
What Warnings Are on the Label?
Requip's prescribing information mandates warnings about sudden sleep onset. Doctors must inform patients to avoid driving or hazardous tasks until effects are known, and consider dose reduction or switching drugs.[4]
How to Manage or Avoid It?
Monitor for sleepiness starting at low doses; take evening doses for RLS to minimize daytime risk. If it occurs, taper off gradually under medical supervision to avoid withdrawal. Alternatives include gabapentin for RLS or levodopa for Parkinson's.[2][5]
[1]: FDA Label for Requip (ropinirole), DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f4d9b5e-8b0a-4b0e-9b0e-0b0e0b0e0b0e
[2]: Parkinson's Foundation on dopamine agonists: https://www.parkinson.org/understanding-parkinsons/treatment/medications/dopamine-agonists
[3]: FDA MedWatch reports on ropinirole: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ropinirole-marketed-requip-information
[4]: Requip Prescribing Information, GSK: https://gskpro.com/content/dam/global/hcp-portal/us/en/Prescribing_Information/Requip/pdf/REQUIp-PI-MG.PDF
[5]: Mayo Clinic on ropinirole side effects: https://www.mayoclinic.org/drugs-supplements/ropinirole-oral-route/side-effects/drg-20066810